A Phase 4 interventional study of Varenicline Tartrate and Placebo in Tobacco Use Cessation, sponsored by Pfizer. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-23.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary goal of this study is to compare efficacy of varenicline to placebo for cessation of use of smokeless tobacco.
276 studies on the registry are indexed under Tobacco Use Cessation; 45 are open to participants now.
This study's enrollment of 432 is above the median of 226 across 256 interventional studies indexed under Tobacco Use Cessation.
Browse Tobacco Use Cessation studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Varenicline Tartrate
Drug: Placebo
Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
Also known as: Champix, Chantix, CP-526,555
Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco
Number of subjects who reported no use of nicotine-containing products by answering "No" to the nicotine use inventory (NUI) question: Has the subject used any nicotine-containing products in the last 7 days (Week 9) or since last study visit (Week 10 through 12) and confirmed salivary cotinine \<= 15 ng/mL.
Time frame: Weeks 9 through 12
Number of Subjects With Continuous Abstinence (CA) of Smokeless Tobacco Use
Number of subjects who remainded abstinent from the period defined as start of the primary endpoint (Week 9) through the end of follow up (Week 26) by reporting no use of nicotine-containing products and confirmed salivary cotinine \<= 15 ng/mL.
Time frame: Week 9 through 12, Week 26
Number of Subjects With Long Term Quit Rate (LTQR) of Smokeless Tobacco
Number of subjects who were responders for the primary endpoint (4-week CQR for Weeks 9 through 12) and who had no more than 6 cumulative days of using nicotine containing products from Week 12 through Week 26.
Time frame: Week 26
Number of Subjects With 7-day Point Prevalence (PP) of Abstinence at the End of Treatment (Week 12) and at the End of Study (Week 26)
Number of subjects at Week 12 and Week 26 reporting no use of nicotine-containing products in the last 7 days and confirmed salivary cotinine \<= 15 ng/mL.
Time frame: Week 12, Week 26
| Milestone | Varenicline Tartrate | Placebo |
|---|---|---|
| Started | 214 | 218 |
| Received treatment | 213 | 218 |
| Completed | 170 | 170 |
| Not completed | 44 | 48 |
| Withdrew: Adverse event | 19 | 9 |
| Withdrew: Lack of efficacy | 3 | 13 |
| Withdrew: Lost to follow-up | 9 | 6 |
| Withdrew: Withdrawal by subject | 12 | 19 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Randomized but not treated | 1 | 0 |
Number of subjects who reported no use of nicotine-containing products by answering "No" to the nicotine use inventory (NUI) question: Has the subject used any nicotine-containing products in the last 7 days (Week 9) or since last study visit (Week 10 through 12) and confirmed salivary cotinine \<= 15 ng/mL.
| participants | Varenicline Tartrate | Placebo |
|---|---|---|
| Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco | 125 | 85 |
Number of subjects who remainded abstinent from the period defined as start of the primary endpoint (Week 9) through the end of follow up (Week 26) by reporting no use of nicotine-containing products and confirmed salivary cotinine \<= 15 ng/mL.
| participants | Varenicline Tartrate | Placebo |
|---|---|---|
| Week 9 | 140 | 101 |
| Week 10 | 135 | 96 |
| Week 11 | 132 | 93 |
| Week 12 | 125 | 85 |
| Week 26 | 95 | 73 |
Number of subjects who were responders for the primary endpoint (4-week CQR for Weeks 9 through 12) and who had no more than 6 cumulative days of using nicotine containing products from Week 12 through Week 26.
| participants | Varenicline Tartrate | Placebo |
|---|---|---|
| Number of Subjects With Long Term Quit Rate (LTQR) of Smokeless Tobacco | 102 | 78 |
Number of subjects at Week 12 and Week 26 reporting no use of nicotine-containing products in the last 7 days and confirmed salivary cotinine \<= 15 ng/mL.
| participants | Varenicline Tartrate | Placebo |
|---|---|---|
| Week 12 | 123 | 85 |
| Week 26 | 102 | 88 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline Tartrate | — | 2/213 (0.9%) | 151/213 (70.9%) |
| Placebo | — | 3/218 (1.4%) | 107/218 (49.1%) |
| Event | Varenicline Tartrate | Placebo |
|---|---|---|
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/213 | 0/218 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/213 | 0/218 |
| Loss of consciousnessNervous system disorders | 1/213 | 0/218 |
| Cardiac failureCardiac disorders | 0/213 | 1/218 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/213 | 1/218 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/213 | 1/218 |
| Event | Varenicline Tartrate | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 74/213 | 14/218 |
| FatigueGeneral disorders | 22/213 | 15/218 |
| HeadacheNervous system disorders | 22/213 | 20/218 |
| Sleep disorderPsychiatric disorders | 22/213 | 15/218 |
| FlatulenceGastrointestinal disorders | 18/213 | 7/218 |
| Abnormal dreamsPsychiatric disorders | 17/213 | 3/218 |
| InsomniaPsychiatric disorders | 13/213 | 6/218 |
| NasopharyngitisInfections and infestations | 12/213 | 8/218 |
| Abdominal pain upperGastrointestinal disorders | 11/213 | 5/218 |
| IrritabilityGeneral disorders | 11/213 | 9/218 |
| Age, Customized(participants) | Varenicline Tartrate | Placebo | Total |
|---|---|---|---|
| 18 - 44 years | 117 | 115 | 232 |
| 45 - 64 years | 88 | 93 | 181 |
| >= 65 years | 8 | 10 | 18 |
| Sex: Female, Male(Participants) | Varenicline Tartrate | Placebo | Total |
|---|---|---|---|
| Female | 24 | 22 | 46 |
| Male | 189 | 196 | 385 |
The record gives a start of Aug 2008, a primary completion of Apr 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline